146 documents

Read All
07:00 , Jun 2, 2014 |  BioCentury  |  Emerging Company Profile

Oncofactor: Revoking immunity

T cell proteins like PD-1 are among the most hotly pursued and promising immuno-oncology targets, but Oncofactor Corp. believes drug developers are just scratching the surface of what proteins are involved in helping tumors avoid...
Read More
07:00 , Apr 8, 2013 |  BioCentury  |  Emerging Company Profile

MAB Discovery: Monitoring maturation

MAB Discovery GmbH is using wild-type animals and blood samples collected at multiple time points during antibody maturation to generate diverse sets of antibodies with high selectivity and affinity for a target antigen. The company...
Read More
07:00 , May 28, 2012 |  BC Week In Review  |  Company News

PPD Inc. management update

PPD Inc., Wilmington, N.C.   Business: Supply/Service   Hired: David Simmons as chairman and CEO, effective June 4, formerly president and general manager of the emerging markets and established products business units at Pfizer Inc.   ...
Read More
08:00 , Dec 12, 2011 |  BC Week In Review  |  Company News

PPD Inc. deal

Asset manager The Carlyle Group and private equity firm Hellman & Friedman completed their acquisition of CRO PPD for $33.25 per share in cash, or $3.9 billion (see BioCentury, Oct. 10). PPD Inc., Wilmington,...
Read More
08:00 , Dec 12, 2011 |  BC Week In Review  |  Clinical News

RBx 10558: Development discontinued

Furiex discontinued development of PPD-10558 after top-line data from a double-blind, U.S. Phase II trial in about 282 patients showed that twice-daily PPD-10558 for up to 12 weeks missed the primary endpoint of significantly reducing...
Read More
01:26 , Dec 10, 2011 |  BC Extra  |  Clinical News

Furiex falls after PPD-10558 discontinuation

Furiex Pharmaceuticals Inc. (NASDAQ:FURX) fell $1.14 to $16.63 on Friday after discontinuing development of PPD-10558 following data that the HMG- CoA reductase inhibitor missed the primary endpoint in a Phase II trial to treat hypercholesterolemia....
Read More
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

Alogliptin/metformin regulatory update

Takeda submitted an NDA to FDA for alogliptin/metformin to treat Type II diabetes. The tablet is a combination of Takeda's alogliptin and metformin. Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is approved for the indication...
Read More
08:00 , Nov 21, 2011 |  BC Week In Review  |  Clinical News

Liovel alogliptin/pioglitazone regulatory update

Takeda said FDA extended the PDUFA date by 3 months for NDAs for 2 Type II diabetes products to April 25, 2012, from Jan. 25. The products are alogliptin and a fixed-dose combination of alogliptin...
Read More
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

Nesina alogliptin regulatory update

Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is approved for the indication in Japan as Nesina. Alogliptin was discovered by Syrrx Inc., which was acquired by Takeda in 2005. PPD Inc. (NASDAQPDI, Wilmington,...
Read More
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Furiex Pharmaceuticals, J&J deal

Johnson & Johnson's Janssen Pharmaceutica N.V. unit did not exercise an option to regain rights to gastrointestinal compound MuDelta from partner Furiex. According to Furiex, Janssen made the decision after evaluating the "strategic fit"...
Read More